EART FAILURE IS THE FASTest growing cardiovascular diagnosis in the United States, with a community prevalence of 2.5% in adults, and the direct and indirect costs of heart failure exceed $33 billion per year. 1 Despite many advances in diagnosis and pharmacotherapy for heart failure during the past 2 decades, morbidity and mortality remain high and quality of life is poor for many patients. Thus, there is increasing enthusiasm for the therapeutic potential of atrial-synchronized biventricular pacemakers (cardiac resynchronization therapy [CRT]) in patients with heart failure and left ventricular (LV) systolic dysfunction. CRT is designed to eliminate the delay in activation of the LV free wall found in many patients with LV systolic dysfunction and thereby improves me-See also Patient Page.